Gary P Wormser

Dr. Gary P Wormser

Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JRJohn Raffalli
John Raffalli
GWGary P Wormser
Gary P Wormser

18 September 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EWErica Weitzner
Erica Weitzner
DMDonna McKenna
Donna McKenna
JNJohn Nowakowski
John Nowakowski
CSCarol Scavarda
Carol Scavarda
RDRhea Dornbush
Rhea Dornbush
GWGary P Wormser
Gary P Wormser
Background. Lyme disease patients with erythema migrans are said to have post-treatment Lyme disease symptoms (PTLDS) if there is persistence of subjective symptoms for at least 6 months following antibiotic treatment and resolution of the skin lesion. The purpose of this study was to characterize PTLDS in patients with culture-confirmed early Lyme disease followed for >10 years. Methods. Adult patients with erythema migrans with a positive skin or blood culture for Borrelia burgdorferi were enrolled in a prospective study beginning in 1991 and followed up at 6 months and annually thereafter to determine the long-term outcome of this infection. The genotype of the infecting strain of B. burgdorferi was evaluated in subjects with PTLDS. Results. One hundred twenty-eight subjects with culture-confirmed early Lyme disease, of whom 55% were male, were followed for a mean ± SD of 14.98 ± 2.71 years (median = 15 years; range = 11–20 years). Fourteen (10.9%) were regarded as having possible PTLDS, but only 6 (4.7%) had PTLDS documented at their last study visit. Nine (64.3%) had only a single symptom. None of the 6 with PTLDS at their last visit was considered to be functionally impaired by the symptom(s). PTLDS was not associated with a particular genotype of B. burgdorferi. Conclusions. PTLDS may persist for >10 years in some patients with culture-confirmed early Lyme disease. Such long-standing symptoms were not associated with functional impairment or a particular strain of B. burgdorferi.

1 April 2019 in Emerging Infectious Diseases
Verified
Journal Article
Open access
GWGary P Wormser
Gary P Wormser
DMDonna McKenna
Donna McKenna
CSCarol Scavarda
Carol Scavarda
DCDenise Cooper
Denise Cooper
MKMarc Y. El Khoury
Marc Y. El Khoury
SWSusan J. Wong
Susan J. Wong
In certain regions of New York state, USA, Ixodes scapularis ticks can potentially transmit 4 pathogens in addition to Borrelia burgdorferi: Anaplasma phagocytophilum, Babesia microti, Borrelia miyamotoi, and the deer tick virus subtype of Powassan virus. In a prospective study, we systematically evaluated 52 adult patients with erythema migrans, the most common clinical manifestation of B. burgdorferi infection (Lyme disease), who had not received treatment for Lyme disease. We used serologic testing to evaluate these patients for evidence of co-infection with any of the 4 other tickborne pathogens. Evidence of co-infection was found for B. microti only; 4–6 patients were co-infected with Babesia microti. Nearly 90% of the patients evaluated had no evidence of co-infection. Our finding of B. microti co-infection documents the increasing clinical relevance of this emerging infection.

1 September 2019 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
HKHarshada Ketkar
Harshada Ketkar
LYLong Yang
Long Yang
GWGary P Wormser
Gary P Wormser
PWPenghua Wang
Penghua Wang

1 March 2019 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
GWGary P Wormser
Gary P Wormser
RWRonald P. Wormser
Ronald P. Wormser
FSFranc Strle
Franc Strle
RMRonnie Myers
Ronnie Myers
BCBurke A. Cunha
Burke A. Cunha

15 November 2017 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PMPhillip J Molloy
Phillip J Molloy
KWKaren E Weeks
Karen E Weeks
BTBrittany Todd
Brittany Todd
GWGary P Wormser
Gary P Wormser
There are no Food and Drug Administration (FDA) approved diagnostic tests for Borrelia miyamotoi infection, an emerging tick-borne illness in the United States. The purpose of this study was to evaluate whether the FDA-approved C6 peptide ELISA currently used to diagnose Lyme disease may potentially serve as a diagnostic test for B. miyamotoi infections. Serum specimens from 30 patients from the Northeastern United States with B. miyamotoi infection established by a polymerase chain reaction assay of a blood specimen were tested using the C6 ELISA. To reduce confounding with B. burgdorferi co-infection, 6 sera were excluded: 3 from patients with a positive Western immunoblot for antibodies to B. burgdorferi and 3 from patients for whom immunoblot testing had not been performed. Twenty-two (91.7%; (95% C.I. 73.0%-98.8%) of 24 evaluable B. miyamotoi patients were C6 ELISA reactive, principally on a convalescent phase serum specimen. C6 ELISA index values were often well above the positive cut-off value of 1.1, exceeding 4 in 11 (50.0%) of the 22 C6 ELISA reactive patients. Although previously regarded as a highly specific test for Lyme disease, the C6 ELISA is also regularly positive on convalescent phase serum samples of patients from the Northeastern United States with B. miyamotoi infection.